US › Healthcare

Passage Bio Inc (PASG)

US · Healthcare · Biotechnology

$4.63+3.12%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-7.6M
Profit YoY
+50.9%
EPS
$-2.36
EPS estimate
$-3.06

EPS came in at -2.36 against a street estimate of -3.06 — a beat of 22.9%.

Key statistics

Market cap
$14.4M
Forward P/E
0.0
P/B
1.22
Book value
$3.66
EPS (TTM)
$-11.84
52-week high
$20.00
52-week low
$3.29
50-day MA
$5.14
200-day MA
$8.01
Beta
1.43

Analyst view

Analysts rate Passage Bio Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $15.50.

Shareholding

Insiders
7.72%
Institutions
58.93%

Largest institutional holders

FundStake
Lynx1 Capital Management, LP19.41%
Vestal Point Capital LP9.49%
Renaissance Technologies Corp4.16%
Eversept Partners, LP4.10%
Vanguard Group Inc3.94%
Vanguard Capital Management, LLC3.55%
Yiheng Capital LLC2.68%
Erste Asset Management GmbH2.65%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Passage Bio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.